Time to ask patients about drugs for macular degeneration

Two of the three treatments we have for wet adult onset macular degeneration are manufactured by the same company—Roche/Novartis. As Cohen explains, now that non-inferiority of outcomes is known, the extreme difference in price continues to cause consternation.1

European law, which exists to protect the public from inferior imports and to promote production of high quality drugs, stipulates that when a drug with marketing …